Institute for Inflammation Research (IIR), Rigshospitalet University Hospital, Copenhagen, Denmark.
J Interferon Cytokine Res. 2010 Oct;30(10):759-66. doi: 10.1089/jir.2010.0091.
This review discusses type I interferon (IFN) immunogenicity with focus on methods of detection of anti-IFN antibodies in patients treated with human recombinant IFN-β. Pitfalls involved in the clinical use of various types of assays for binding antibodies and neutralizing antibodies against IFN-β are presented, and the widely held distinction between binding antibodies and neutralizing antibodies is questioned both in terms of detection and clinical importance. The article also addresses important bioavailability and pharmacokinetic issues occurring with prolonged use of protein drugs. The rationale for individualized or personalized medicine, ie, optimizing therapies according to individual needs rather than using standardized trial-and-error regimens to all patients, is highlighted.
这篇综述讨论了 I 型干扰素（IFN）的免疫原性，重点介绍了检测接受人重组 IFN-β治疗的患者体内抗 IFN 抗体的方法。本文介绍了在临床使用针对 IFN-β的结合抗体和中和抗体的各种检测方法时可能出现的问题，并对区分结合抗体和中和抗体的观点提出质疑，包括检测方法和临床重要性两方面。文章还讨论了长期使用蛋白质药物时出现的重要生物利用度和药代动力学问题。强调了个体化或个性化医学的基本原理，即根据个体需求优化治疗，而不是对所有患者使用标准化的尝试和错误方案。
